Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Arthrotec

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
B B
B B

Misoprostol Testmiljö

Misoprostol

Klass : B

  1. Cytotec (misoprostol). Summary of Product Characteristics. Medical Products Agency (MPA); 2012.
  2. Physicians' Digital Reference. http://www.pdr.net. [cited 2017-07-12].
  3. CYTOTEC (misoprostol). Summary of Product Characteristics. http://www.medicines.org.uk/emc [cited 2017-07-12]
  4. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:iii-iv, 1-164.
  5. Hawkey CJ, Wilson I, Naesdal J, Långström G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51:344-50.
  6. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-34.
  7. Misoprostol (misoprostol) DailyMed. DailyMed [www]. US National Library of Medicine. [updated 2016-02-12, cited 2017-07-12].
  8. Waiser J, Böhler T, Stoll J, Schumann B, Budde K, Neumayer HH. The immunosuppressive potential of misoprostol--efficacy and variability. Clin Immunol. 2003;109:288-94.
  9. Bergmann JF, Pichot L, de Pouvourville G, Chassany O, Caulin C, Segrestaa JM. [Prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents Economic analysis from a survey of 356 physicians]. Presse Med. 1992;21:979-82.
  10. Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice A general practitioner-based survey in France. Eur J Clin Pharmacol. 2001;57:737-43.
  11. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9.
A A
A A

Diklofenak Testmiljö

Diklofenak

Klass : A

  1. Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB et al. Studying sex and gender differences in pain and analgesia: a consensus report. Pain. 2007;132 Suppl 1:S26-45.
  2. Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013;111(1):52-8.
  3. Sorge RE, Totsch SK. Sex Differences in Pain. J Neurosci Res. 2017;95(6):1271-1281.
  4. Dance A. Why the sexes don't feel pain the same way. Nature. 2019;567(7749):448-450.
  5. Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy. 2009;29:1397-407.
  6. García Rodríguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994;154:311-6.
  7. Lacroix I, Lapeyre-Mestre M, Bagheri H, Pathak A, Montastruc JL, Club de Reflexion des cabinets de Groupe de Gastro-Enterologie (CREGG) et al. Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol. 2004;18:201-6.
  8. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95-106.
  9. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging. 2009;26:769-79.
  10. Voltaren (diklofenak). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2020-11-25, cited 2021-12-13]
  11. Salman S, Sherif B, and Al-Zohyri A. OP0131 Effects of Some Non Steroidal Anti-Inflammatory Drugs on Ovulation in Women with Mild Musculoskeletal Pain. Annals of the Rheumatic Diseases. 2015;74(suppl 2):117-118.
  12. Stone S, Khamashta MA, Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link?. Drug Saf. 2002;25:545-51.
  13. Uhler ML, Hsu JW, Fisher SG, Zinaman MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril. 2001;76(5):957-61.
  14. Matyas RA, Mumford SL, Schliep KC, Ahrens KA, Sjaarda LA, Perkins NJ et al. Effects of over-the-counter analgesic use on reproductive hormones and ovulation in healthy, premenopausal women. Hum Reprod. 2015;30(7):1714-23.
  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]
  16. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]